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The mycobacterial biotin protein ligase (MtBPL)
globally regulates lipid metabolism in Mtb through
the posttranslational biotinylation of acyl coenzyme
A carboxylases involved in lipid biosynthesis that
catalyze the first step in fatty acid biosynthesis and
pyruvate coenzyme A carboxylase, a gluconeogenic
enzyme vital for lipid catabolism. Here we describe
the design, development, and evaluation of a ratio-
nally designed bisubstrate inhibitor of MtBPL. This
inhibitor displays potent subnanomolar enzyme
inhibition and antitubercular activity against multi-
drug resistant and extensively drug resistant Mtb
strains. We show that the inhibitor decreases in vivo
protein biotinylation of key enzymes involved in
fatty acid biosynthesis and that the antibacterial
activity is MtBPL dependent. Additionally, the gene
encoding BPL was found to be essential in
M. smegmatis. Finally, the X-ray cocrystal structure
of inhibitor bound MtBPL was solved providing
detailed insight for further structure-activity analysis.
Collectively, these data suggest that MtBPL is
a promising target for further antitubercular thera-
peutic development.
INTRODUCTION
Tuberculosis (TB) caused by the bacterium Mycobacterium
tuberculosis (Mtb) continues to burden human health on a global
scale. Despite an impressive amount of effort directed at eradi-
cating tuberculosis, TB is still the second leading cause of
mortality among infectious diseases superseded only by HIV.
The emergence of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) TB strains coupled with the high incidence
of HIV-TB coinfection and the lack of any new approved chemo-
therapeutic agents for TB in over four decades, demands the
development of new antitubercular agents, ideally with novel
mechanisms of action, to combat this devastating pathogen.
Fatty acid biosynthesis is a validated pathway for antituber-
cular drug discovery, and the first-line agent isoniazid inhibits1432 Chemistry & Biology 18, 1432–1441, November 23, 2011 ª2011the type II fatty acid synthase (FAS-II) in Mtb (Slayden et al.,
2000; Timm et al., 2003). Acyl coenzyme A carboxylases
(ACCs) catalyze the first committed step in fatty acid biosyn-
thesis through synthesis of themonomeric malonyl-CoA building
blocks. However, unlike most bacteria that encode for a single
ACC complex, Mtb encodes for multiple ACCs responsible for
the biosynthesis of malonyl coenzyme A (CoA), (methyl)malonyl
CoA, and (C22–C24) malonyl CoA for construction of the struc-
turally diverse lipids in Mtb, including simple linear fatty acids,
methyl-branched lipids, and mycolic acids (Gago et al., 2006;
Kurth et al., 2009; Portevin et al., 2005). In order for the ACCs
to become functionally active, the biotin-carboxylase carrier
protein (BCCP) domains of these proteins must be posttransla-
tionally modified to their active holo biotinylated form by a biotin
protein ligase (BPL) encoded by birA in Mtb (MtBPL) (Purusho-
thaman et al., 2008). The biotin serves as the cofactor that medi-
ates carboxyl group transfer onto the acetyl CoA substrates. In
addition to fatty acid biosynthesis, fatty acid degradation is
also an essential process, and mycobacteria are thought to be
primarily lipolytic in vivo deriving their energy via fatty acid catab-
olism (Timm et al., 2003).MtBPL may also play a key role in fatty
acid degradation, because this enzyme is also responsible for
biotinylation of the BCCP domain of pyruvate carboxylase,
which can channel oxaloacetate to the phosphoenolpyruvate
carboxykinase, a gluconeogenic enzyme that is essential for
growth on fatty acids and critical for mycobacterial pathogenesis
(Marrero et al., 2010).MtBPL thus globally regulates lipid metab-
olism and represents an attractive target for development of new
antitubercular agents.
There are two classes of biotin protein ligases (BPLs):
the monofunctional enzymes represented by the BPL from
Pyrococcus horikoshii (PhBPL), which solely catalyze posttrans-
lational biotinylation, and the bifunctional enzymes represented
by the prototypical BPL from Escherichia coli (EcBPL), which
also act as transcriptional repressors (Brown et al., 2004;
Chapman-Smith and Cronan, 1999). Recent biochemical char-
acterization of the BPL from Mtb (MtBPL) has revealed it to be
a monofunctional enzyme that exists as a monomer in both the
unliganded apo-and holo-forms as well as in the biotinyl adeny-
late (Bio-AMP, 2) liganded form (Purushothaman et al., 2008).
BPLs catalyze the transfer of biotin onto a conserved lysine
residue of the biotin-carboxylase carrier protein (BCCP) domain
of ACCs. This reaction is accomplished in two steps: in the first-
half reaction, BPLs bind biotin (1, Figure 1A) and ATP andElsevier Ltd All rights reserved
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Figure 1. Enzyme Reaction Catalyzed by BPL
(A) First half-reaction to form biotin adenylate.
(B) Second half-reaction involving transfer of biotin to acetyl CoA carboxylases.
(C) Bisubstrate inhibitors of BPL and degradation products of 5.
See also Figure S1.
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Inhibition of M. tuberculosis Biotin Protein Ligasecatalyze the nucleophilic attack of the biotin carboxylate onto the
a-phosphate of ATP to yield the acyl-adenylate Bio-AMP 2
(Figure 1A) and pyrophosphate. In the second-half reaction,
BPLs transfer biotin from Bio-AMP 2 onto a conserved lysine
residue within the BCCP domain 3 to provide biotinylated-
BCCP 4 (Figure 1B). The bisubstrate inhibitor 5 (Figure 1C) has
been described, which mimics the intermediate acyl-adenylate
Bio-AMP 2 by replacement of the labile acylphosphate linkage
in Bio-AMP 2 with the bioisosteric acylsulfamate moiety
(Brown and Beckett, 2005; Brown et al., 2004). Interestingly,
the bisubstrate inhibitor 5 was found to bind 1.4-fold more
weakly to EcPBL than the single substrate biotin, suggesting
the acylsulfamate was a poor isostere for the native acylphos-
phate linkage.
Here we describe the design, synthesis, biochemical, struc-
tural, and biological evaluation of a bisubstrate inhibitor of
MtBPL that we term Bio-AMS (6, Figure 1C) which binds more
than 1700-fold more tightly than biotin and possesses potent
and selective antimicrobial activity against MDR- and XDR-TB
strains of Mtb. We used M. smegmatis to confirm that the
BPL-encoding gene, birA, is essential as well as to assess
susceptibility of MtBPL to inhibition in vivo. Support for the de-
signed mechanism of action is provided using a combination
of proteomic profiling and genetic studies. Finally, we describe
the detailed molecular interactions present between MtBPL
and Bio-AMS that establish the molecular basis for potent inhibi-
tion and provides a framework for future structure-aided drug
design.Chemistry & Biology 18, 1432–144RESULTS
Inhibitor Design and Synthesis
Bisubstrate inhibitors that mimic acyl-adenylate reaction inter-
mediates typically bind much more tightly than the individual
substrates owing to the large number of interactions between
the inhibitor and both substrate binding sites (Ferreras et al.,
2005; Somu et al., 2006). The reported lack of potency of 5
toward EcBPL is surprising (Brown and Beckett, 2005), so we
synthesized this compound as described in Supplemental
Experimental Procedures. We immediately observed that it is
chemically unstable and decomposes through cyclonucleoside
formation to afford N-biotinylsulfamic acid 7 (Figure 1C) and
3,50-cyclo-50-deoxyadenosine 8 (experimental details and com-
plete characterization are found in the Supplemental Informa-
tion). We hypothesized that a more stable compound would
result if the 50-oxygen atom in sulfamate 5 were replaced with
a nitrogen atomof sulfamide 6 as a result of the decreased nucle-
ofugality of the sulfamide (Broeckaert et al., 2008). Compound 6
(Bio-AMS) was synthesized, and as predicted, it did not undergo
cyclonucleoside formation. Because of its improved stability,
Bio-AMS represents an excellent probe to chemically validate
MtBPL as a target for antitubercular therapeutic development.
Biochemical Evaluation of Bio-AMS
We next evaluated Bio-AMS in a kinetic continuous coupled
assay with 250 nM MtBPL to determine the concentration-
response curve for inhibition of MtBPL at fixed saturating1, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1433
180
116
97
57
40
29
20
14
0 0.1 1.0
0
25
50
75
100
Bio-AMS, µM
n
o
rm
a
liz
e
d
%
ba
nd
 
in
te
ns
ity
0 250 500 750 1000
0.0
0.2
0.4
0.6
0.8
1.0
Bio-AMS, nM
v
i  /v
0
M           1            2            3
A B
C D
Molar Ratio of Bio-AMS:MtBPL
Time, min
0          20          40         60          80        100        120
c
es/l
acµ
t
n
atc
ej
nif
ol
o
m/l
ack
9.6
9.4
9.2
9.0
8.8
0
-2
-4
-6
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2
Figure 2. In Vitro Analysis and Mechanism of Action Studies of Bio-AMS Inhibitor
(A) Dose-response of MtBPL with inhibitor Bio-AMS. vi and v0 are velocities of inhibitor and DMSO treated samples, respectively.
(B) Competitive ITC trace of a solution of Bio-AMS (200 mM) in 10 mM Tris (pH 7.5), 200 mM KCl, and 2.5 mMMgCl2 titrated into a solution ofMtBPL (20 mM) and
biotin (150 mM) in the same buffer.
(C) Western blot analysis of biotinylated protein levels in lysates from Mtb H37Rv cells treated with varying concentrations of Bio-AMS. Lane M: biotinylated
molecular weight marker; Lane 1, DMSO-treated MTB cells; Lane 2,Mtb cells treated with 0.1 mMBio-AMS; Lane 3:Mtb cells treated with 1.0 mMBio-AMS. The
dashed box corresponds to the section of the gel that was excised for trypsin digestion and LC-MS/MS analysis.
(D) Normalized band intensities of bands in lanes 1–3 from (C).
See also Figure S2 and Table S2.
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Inhibition of M. tuberculosis Biotin Protein Ligasesubstrate concentrations. As shown in Figure 2A, the half-
maximum inhibitor concentration (IC50 = 135 ± 9 nM) is approx-
imately equal to half of the enzyme concentration, a character-
istic inherent to tight-binding inhibitors (Copeland, 2005).
Attempts to determine the true inhibition constant (Ki) were
complicated by the tight-binding behavior and the bisubstrate
nature of inhibition, which precluded assessment by traditional
steady-state kinetic methods (Yu et al., 2006).
We employed isothermal titration calorimetry (ITC) to investi-
gate the binding affinity of Bio-AMS for MtBPL. Accurate
determinations of the binding constants using ITC are typically
limited to a range of 103108 M1 (Sigurskjold, 2000). A more
reliable approach for determining binding constants greater
than 108 M1 is to use displacement ITC in which a high-affinity
inhibitor is titrated into a solution of protein that is bound with
a weaker ligand (Leavitt and Freire, 2001; Velazquez-Campoy
et al., 2001). Displacement ITC experiments were performed
(Figure 2B) using biotin as the competitive ligand to obtain values
for KA and n (Experimental Procedures). The binding enthalpy
was determined by stoichiometric titration of MtBPL with Bio-1434 Chemistry & Biology 18, 1432–1441, November 23, 2011 ª2011AMS at a high c value (Experimental Procedures). The thermody-
namic parameters are listed in Table 1. The ITC studies provided
an experimental KD of 0.53 ± 0.13 nM with an n value of 1.12 ±
0.02 indicating one substrate binding site per MtBPL monomer.
Bio-AMS binds approximately 1700-fold more tightly to MtBPL
than biotin (Table 1) (Purushothaman et al., 2008). The binding
is solely enthalpically driven (DH = 15.4 ± 0.1 kcal/mol) with an
unfavorable entropic component (TDS = 3.0 ± 0.0 kcal/mol).
The large observed enthalpic component is commonly observed
among tight-binding bisubstrate inhibitors and can be attributed
to numerous hydrogen bonds and electrostatic interactions
between inhibitor and protein (Neres et al., 2008; Sikora et al.,
2010).
Antitubercular Activity, Antimicrobial Specificity,
and Therapeutic Index
The antitubercular activity of Bio-AMS was evaluated against
MtbH37Rv, the common laboratory virulent strain. Theminimum
inhibitory concentration that inhibited greater than 99% of cell
growth (MIC99) is 0.31–0.78 mM (Table 2). On the basis of theElsevier Ltd All rights reserved
Table 1. Thermodynamic Parameters of Bio-AMS Binding to MtBPL
n KD, nM DH, kcal mol
1 DG, kcal mol1 TDS, kcal mol1
Biotina 0.98 940 11.1 8.1 3.0
Bio-AMS 1.12 ± 0.02 0.530 ± 0.134 15.4 ± 0.1 12.4 ± 0.1 3.0 ± 0.0
a Thermodynamic values for biotin were taken from Purushothaman et al. (2008).
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Inhibition of M. tuberculosis Biotin Protein Ligasepromising antitubercular activity, we then tested Bio-AMS
against ten phenotypically characterized MDR and XDR TB
strains. The MIC99 values range from 0.16 to 0.625 mM
(Table 2) demonstrating that Bio-AMS is equally effective
against susceptible and MDR- and XDR-TB strains. We also
tested the ability of Bio-AMS to inhibit cell growth in other bacte-
rial and fungal strains because BPLs are present in most organ-
isms. Remarkably, Bio-AMS was inactive against a panel of
gram-negative bacteria (A. baumannii, E. coli, K. pneumoniae
and P. aeruginosa,), gram-positive bacteria (E. faecalis and
S. aureus), and fungi (C. neoformans, and C. albicans) (see Table
S1 available online). We speculate the antimicrobial specificity
results from limited intracellular accumulation due to differences
in cellular penetration and efflux, rather than biochemical selec-
tivity. Because mammals also contain a biotin protein ligase
(holocarboxylase synthetase; Campeau and Gravel, 2001), we
evaluated the cytotoxicity of Bio-AMS against two mammalian
cell lines, Vero cells and DU145 human prostate cells. DU145Table 2. Biological Activity and Selectivity of Bio-AMS
Strain/Cell Line Resistance Phenotypea
M. tuberculosis H37Rv Wt
M. tuberculosis XDR-1 HRESPOCTh
M. tuberculosis XDR-2 HREPKOTh
M. tuberculosis MDR-1 HRESPO
M. tuberculosis MDR-2 HREKO
M. tuberculosis MDR-3 HRESP
M. tuberculosis MDR-4 HRCPTh
M. tuberculosis MDR-5 HRERb
M. tuberculosis MDR-6 HREZSKPTh
M. tuberculosis MDR-7 HRERb
M. tuberculosis MDR-8 HREZRbTh
A. baumannii -
E. coli -
K. pneumoniae -
P. aeruginosa -
E. faecalis -
S. aureus MRSA
C. albicans -
C. neoformans -
DU145 na
Vero na
The following ATCC strains were used: A. baumannii, 19606; E. coli, 25922
S. aureus, MRSE, 43300; C. albicans, 10231; C. neoformans, 66031. na, no
a Letter codes represent drugs which that strain is resistant to. H = isoniazid;
acid; O = ofloxacin; Th = thiacetazone; C = capreomycin; K = kanamycin; R
bXDR = extensively drug-resistant; MDR = multidrug-resistant.
c Vero cells were still 25% viable at 500 mM.
Chemistry & Biology 18, 1432–144cells were insensitive to Bio-AMS, whereas Bio-AMS displayed
very low cell cytotoxicity to Vero cells inhibiting 50% growth
(CC50) at 58 mM providing a therapeutic index (CC50/MIC99) of
74–187 on the basis of the MIC against Mtb H37Rv.
Mechanism of Action
To demonstrate that Bio-AMS inhibits protein biotinylation
in vivo, a culture of Mtb H37Rv was treated with Bio-AMS
(0.1 mM or 1.0 mM) along with a DMSO control. After treatment
for 26 hr, cells were harvested and lysed. Protein concentrations
were determined, and lysates were separated by denaturing
gel electrophoresis and imaged via western blot (Figure 2C).
The biotinylated protein pattern of the DMSO treated cells
(lane 1) shows two biotinylated proteins above 100 kDa, one of
which is likely pyruvate carboxylase. Additionally, the proteins
between 55–80 kDa are most likely the acyl CoA carboxylases
(accA1–A3). Lastly, there is one unidentified biotinylated protein
that is approximately 25 kDa. When Mtb was incubated withClassificationb MIC99 (mM) EC50 (mM)
– 0.31–0.78 –
XDR 0.625 –
XDR 0.625 –
MDR 0.16 –
MDR 0.16 –
MDR 0.625 –
MDR 0.625 –
MDR 0.625 –
MDR 0.625 –
MDR 0.625 –
MDR 0.625 –
Gram-negative >400 –
Gram-negative >400 –
Gram-negative >400 –
Gram-negative >400 –
Gram-positive >400 –
Gram-positive >400 –
Fungal >400 –
Fungal >400 –
Mammalian – >100
Mammalian – 58c
; K. pneumoniae, 13883; P. aeruginosa, 27853; E. faecalis, VRE, 51299;
t applicable.
R = rifampicin; E = ethambutol; S = streptomycin; p = para-aminosalicylic
b = rifabutin; Z = pyrazinamide.
1, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1435
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Figure 3. Impact of MtBPL Expression on Drug Susceptibility of M. smegmatis and Mtb
(A–D) In (A) and (C), 10 mg of total protein extracts of the indicated strains were used to measure MtBPL expression by western blotting. Enolase (lower panels)
served as the loading control. (B) and (D) show susceptibility ofM. smegmatis (MtBPL-H [black],MtBPL-M [blue], andMtBPL-L [red]) andMtb (MtBPL-H [black],
MtBPL-M [blue], andwt [red]) to BioAMS. Normalized growth was calculated as OD580 at the indicated drug concentration divided by OD580 without drug. Error
bars represent SEMs of 4 to 8 measurements.
See also Figures S3–S5.
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Inhibition of M. tuberculosis Biotin Protein Ligase0.1 mM (1/3–1/8 3 MIC99, lane 2), a minimal decrease in band
intensity (protein biotinylation) was seen. However, when 1.0 mM
Bio-AMS (1.5–3 3 MIC99, lane 3) was incubated with Mtb,
a clear decrease in protein biotinylation of all bands were
observed. Band intensities in each lane were calculated and
normalized to the amount of protein loaded into each well to
provide normalized biotinylation levels (Figure 2D). The bio-
tinylated proteins highlighted by the dashed box in Figure 2C
were confirmed to be the acetyl/propionyl CoA carboxylases
by mass spectrometry (Figure S2 and Table S2). Because cells
were treated with Bio-AMS for only 26 hr before being harvested,
the slow doubling time ofMtb (24 hr in GAST medium) likely pre-
vented growth arrest in the presence of inhibitor, but still allowed
for a measurable decrease in protein biotinylation. These results
clearly demonstrate that Bio-AMS decreases global biotinylation
levels of proteins involved in fatty acid biosynthesis.
Validation of the Essentiality of birA in M. smegmatis
and Susceptibility to Inhibition by Bio-AMS
For genetic studies, we first turned to M. smegmatis, a fast-
growing mycobacterium whose genome encodes homologs
for each of the three ACC alpha subunits and the six ACC beta1436 Chemistry & Biology 18, 1432–1441, November 23, 2011 ª2011subunits of Mtb and that, like the genome of Mtb, contains
a single BPL-encoding gene (MsbirA). After repeated attempts
to delete MsbirA in wild-type (WT) M. smegmatis had failed, we
constructed a merodiploid strain, which contained a second
MsbirA integrated into the attachment site of the phage L5.
This allowed us to delete the WT copy of MsbirA resulting in
M. smegmatis DMsbirA MsbirA-attL5 (Figures S3 and S4), and
to subsequently demonstrate that M. smegmatis is unable to
form colonies on agar plates without MsbirA (Figure S3). We
next used M. smegmatis DMsbirA MsbirA-attL5 to show that
theMtb birA gene, MtbirA, can replaceMsbirA and constructed
threeM. smegmatis strains,MtBPL-H,MtBPL-M, andMtBPL-L,
which instead ofMsBPL express high, intermediate, or low levels
of MtBPL, respectively (Figure 3A). These M. smegmatis strains
all grew normally in liquid media (Figure S5A), but their suscepti-
bility to Bio-AMS increased with decreasing expression of
MtBPL (Figure 3B). By contrast, these strains showed identical
susceptibilities to isoniazid (INH) and ethambutol (EMB) (Figures
S5B and S5C). Next, we generated twoMtb strains,MtbMtBPL-
H and MtBPL-M, which overexpressed MtBPL to different
degrees (Figure 3C). Overexpression of MtBPL did not affect
growth (not shown) or susceptibility of Mtb to INH (Figure S5D)Elsevier Ltd All rights reserved
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Figure 4. Structure of Bio-AMS with MtBPL
(A) The MtBPL binding site showing the loops undergoing the order-to-disorder transition (gray) upon binding of Bio-AMS (green carbons). Specific hydrogen
bonds are shown in yellow dashes. Asn130 is omitted for clarity.
(B) Schematic view of polar interactions between biotin (purple), acylsulfamide linker (red/green), ribose (orange), and adenosine (blue) portions of Bio-AMS and
MtBPL. See also Figure S6 and Table S3.
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Inhibition of M. tuberculosis Biotin Protein Ligasebut did decrease susceptibility to Bio-AMS (Figure 3D). Taken
together, these experiments demonstrated (1) that MsbirA is
essential for growth ofM. smegmatis, (2) thatMtbirA can replace
MsbirA, and (3) that the BPL expression level specifically deter-
mines susceptibility of M. smegmatis and Mtb to Bio-AMS.
Cocrystal Structure
To identify important molecular interactions critical to the
potency of Bio-AMS, we solved the cocrystal structure with
MtBPL to 1.7-A˚ resolution (see Figure S6 and Table S3 for
data collection and refinement statistics). Compared to the
apo structures of MtBPL (Gupta et al., 2010; Ma and Wilmanns,
2007), the complex structure reveals that two loops (residues
65–76 and 162–169) undergo a disorder-to-order transition
upon binding of Bio-AMS and form extensive, specific contacts
(Figure 4), consistent with the displacement ITC results. The
biotin moiety and adenine nucleobase are recognized by
a common constellation of hydrogen bonds observed in all
liganded biotin-protein ligase crystal structures to date (Bagaut-
dinov et al., 2005; Tron et al., 2009; Wood et al., 2006). The
adenine nucleobase is specifically recognized via hydrogen
bonds with the side chain of Asn158 and backbone of Ala75.
Consistent with Bio-AMS being competitive with biotin, the
buried urea moiety of biotin is hydrogen bonded to the
backbone carbonyl and amide of Arg67, the hydroxyl of Ser38,
the side-chain amide of Gln63, and the hydroxyl of Thr39. Anal-
ogous to the isosteric 50-biotinyl-AMP structures reported from
Pyrococcus hiorikoshii (Bagautdinov et al., 2005), Trp74 packs
between the adenine ring and the alkyl tail of biotin. In contrast
to all other reported biotin-protein ligase structures, MtBPL
possesses a unique interaction between the side-chain amide
of Gln81 and both the indole nitrogen of Trp74 and carbonyl
of Ala75. Likely unique to MtBPL, Asp167 interacts with the
20-hydroxyl of the ribose; the only other reported interaction
between a ribose hydroxyl and a BPL is seen with Gln221 on
a separate portion of the ordered loop with the EcBPL (Wood
et al., 2006). With the acylsulfamide linkage, there are extensiveChemistry & Biology 18, 1432–144interactions between the guanidinium groups of Arg69 and
Arg72 and the side chain of Asn130 with the sulfamide oxygens.
Because of the low pKa of the central nitrogen of the acylsulfa-
mide linker, it is likely in the deprotonated amide form; the crystal
structure supports this with a hydrogen bond distance of 3.0 A˚
with good geometry to the backbone N-H of Arg69. The terminal
amine of Lys138, which is thought to be critical for adenylation
reaction, interacts with and stabilizes the amide oxygen of the
acylsulfamide linker, one sulfamide oxygen, the carboxylate of
Asp131, and a water molecule that is hydrogen bonded to the
distal nitrogen of the sulfamide linkage.
DISCUSSION
Bio-AMS is considered a bisubstrate inhibitor because it inter-
actswith both substrate (biotin and ATP) binding pockets. Bisub-
strate inhibitors (A–B) can realize substantial enhancement in
binding energy compared to the sum of the Gibbs binding ener-
gies of the respective fragments (A + B) because of a smaller
entropy barrier to binding of A–B compared to A + B (Jencks,
1981). Thus, the report that 50-O-[N-(biotinyl)sulfamoyl]adeno-
sine 5 bound more weakly than the single substrate biotin was
incongruous, particularly in light of several recent reports
demonstrating related bisubstrate inhibitors bound with high
affinity (Brown and Beckett, 2005; Ferreras et al., 2005; Somu
et al., 2006). Competitive displacement isothermal titration calo-
rimetry revealed the true potency of Bio-AMS, providing a KD of
0.530 nM that is driven exclusively by a large favorable enthalpy
of 15.4 kcal/mol. The high affinity and favorable thermo-
dynamic parameters exhibited in the interaction of MtBPL with
Bio-AMS correlates well with the detailed molecular interactions
observed (Figure 4). The large number of hydrogen bonds and
the electrostatic interactions with Lys138 and the backbone of
Arg69 result in the large, favorable enthalpy. The conformational
restriction of the ligand within the binding pocket, combined with
the disorder-to-order transition observed for the two loops of
MtBPL covering Bio-AMS, is likely compensated for by the1, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1437
Chemistry & Biology
Inhibition of M. tuberculosis Biotin Protein Ligaseincreased hydrophobic interactions with the alkyl tail of biotin
and Trp74 to net only a small unfavorable entropy.
Another important finding from our work was the demonstra-
tion that 5 slowly decomposes through cyclonucleoside forma-
tion, which has precedent in related 50-activated nucleosides
(Kristinsson et al., 1995; Liang et al., 2008; Yanachkov and
Wright, 1994). Replacement of the 50-oxygen atom in 5 with
a nitrogen atom afforded the more stabile acylsulfamide linkage
of Bio-AMS. Although the acylsulfamate linkage has historically
been used as a bioisostere of the acylphosphate to generate ad-
enylate inhibitors, caution is warranted because of its potential
lack of stability. Several strategies exist to improve the stability
including replacement of the 50-oxygen with a nitrogen atom as
shown herein or a carbon atom. Alternate strategies to prevent
the undesired cyclonucleoside formation include installation of
a bulky group at the C-2 position of the adenine ring to hinder
the required syn conformation about the glycosidic linkage or
deletion of the N-3 nitrogen atom of adenine to prevent nucleo-
philic attack. As demonstrated in this work, the replacement of
the 50 oxygen with a nitrogen provides the required stability while
maintaining isostere integrity.
The observation that Bio-AMS exhibited potent whole-cell
activity towardMtbwas unexpected. Indeed, related acyladeny-
late bisubstrate inhibitors developed for the functionally related
aminoacyl tRNA synthetases have typically been devoid of
whole-cell activity owing to the limited membrane permeability
of these highly polar nucleoside analogs (Hurdle et al., 2005;
Kim et al., 2003; Pohlmann and Bro¨tz-Oesterhelt, 2004). Myco-
bacteria are considered to have the most complex and fortified
cellular wall of any bacterial species; thus, the potent and
selective antitubercular activity was intriguing. However, the
ability of these bisubstrate adenylate inhibitors to cross the cell
wall of Mtb is not unprecedented, because our laboratory and
others have shown that these inhibitors possess potent whole-
cell antitubercular activity (Ferreras et al., 2005; Somu et al.,
2006). We hypothesize that the observed selectivity is likely
due to selective accumulation facilitated by one of the 30
ATP-binding cassette (ABC) transporters present in Mtb (Brai-
bant et al., 2000) that are responsible for assimilation of nucleo-
sides and cofactors.
Biotinylation, catalyzed by the mycobacterial biotin protein
ligase MtBPL, is a posttranslation modification that represents
a key nodal point in mycobacterial fatty acid metabolism and
controls flux through both fatty acid biosynthetic and catabolic
pathways. We designed and synthesized the bisubstrate inhib-
itor Bio-AMS, which was shown by isothermal titration calorim-
etry to bind MtBPL with a subnanomalor dissociation constant.
Despite its highly polar structure, Bio-AMS also displayed
impressive whole-cell activity against Mtb H37Rv, as well as
a panel of MDR and XDR Mtb strains. The selective antituber-
cular activity of this compound is intriguing andmay be the result
of selective mycobacterial accumulation. Further biochemical
and cell-based accumulation studies will be required to delin-
eate the origin of the remarkable selective antitubercular activity.
Nevertheless, our genetic experiments with M. smegmatis
demonstrated that MsbirA is an essential gene and also con-
firmed that the antibacterial activity of Bio-AMS is BPL depen-
dent. Proteomic analysis demonstrated that Bio-AMS also
inhibits protein biotinylation in Mtb. The detailed molecular1438 Chemistry & Biology 18, 1432–1441, November 23, 2011 ª2011interactions visualized in the cocrystal structure of MtBPL with
Bio-AMS pinpoint key opportunities to engineer selectivity and
further augment binding affinity. Thus, the work presented here
validates MtBPL as an attractive target for the development of
novel antitubercular agents. Beyond their role as potential antitu-
bercular agents, Bio-AMSmay also find utility as tool compound
for chemical biology studies because biotinylation is widely used
for site-specific protein labeling and other biotechnological
applications.
SIGNIFICANCE
With the rapid emergence of drug-resistant strains ofMyco-
bacterium tuberculosis comes the need to identify new drug
targets and develop small molecule inhibitors for these
enzymes. Here, we synthesized a potent bisubstrate inhib-
itor for studying a promising enzyme target from Mtb. In
designing this inhibitor, we have identified an important
decomposition mechanism among bisubstrate adenylation
inhibitors, indicating that careful attention needs to be
given to engineering stability into these small molecules.
The cocrystal structure of the inhibitor-bound BPL enzyme
provides key insight into the structural differences between
BPL from Mtb and other organisms, which builds the foun-
dation for future medicinal chemistry efforts. Additionally,
these studies use genetic knockdowns to determine the
mechanism of action of a new small molecule probe in
mycobacteria. Lastly, our genetic knockout results demon-
strate that BPL is an essential enzyme, further validating
this enzyme as a promising candidate target for antibiotic
development.
EXPERIMENTAL PROCEDURES
See Supplemental Information for full synthetic procedures, cloning and
expression of MtBPL, antimicrobial and cytotoxicity assays, and biotinylated
protein identification.
Bio-AMS Synthesis
Bio-AMS was synthesized in two steps starting from 50-amino-50-N-tert-
butoxycarbonyl-50-deoxy-20,30-O-isopropylidene-50-N-(sulfamoyl)adenosine
(S5 (Lu et al., 2008), Supplemental Scheme S3) in 55% overall yield. Biotin was
coupled to S5 (Lu et al., 2008) followed by global TFA deprotection to yield
crude Bio-AMS (6). The title compound was purified by reverse phase
HPLC. Detailed experimental procedures are provided in the Supplemental
Information: 1H NMR (600 MHz, DMSO-d6) d 0.96 (t, J = 4.8 Hz, 18H, 2 equiv.
TEA), 1.22–1.33 (m, 2H), 1.39–1.50 (m, 3H), 1.57–1.63 (m, 1H), 2.08 (t, J =
7.2 Hz, 2H), 2.49 (p, J = 1.8 Hz, 9H, 2 equiv. TEA), 2.56 (d, J = 5.4 Hz, 1H),
2.79 (dd, J = 12.6, 4.8 Hz, 1H), 3.05 (ddd, J = 8.4, 6.1, 4.7 Hz, 1H), 3.09 (dd,
J = 13.2, 4.2 Hz, 2H), 4.03 (dd, J = 7.2, 4.2 Hz, 1H), 4.09–4.11 (m, 2H), 4.26
(dd, J = 7.8, 5.4 Hz, 1H), 4.68 (q, J = 4.8 Hz, 1H), 5.25 (s, 1H) 5.43 (d, J =
6.0 Hz, 1H), 5.82 (d, J = 6.6 Hz, 1H), 6.34 (s, 1H), 6.52 (s, 1H), 7.38 (s, 2H),
8.18 (s, 1H), 8.29 (s, 1H); 13C NMR (150 MHz, CD3OD) d 11.7, 25.7, 28.5,
28.7, 37.3, 40.5, 45.8, 46.2, 55.8, 59.6, 61.5, 71.8, 73.1, 84.1, 88.5, 119.9,
140.7, 149.4, 153.0, 156.7, 163.2, 173.2; HRMS (ESI–) calcd for
C20H28N9O7S2 [M  H] 570.1559, found 570.1523 (error 6.3 ppm).
Kinetic Inhibition Assays
Enzyme assays to determine the IC50 value for Bio-AMS were run under initial
velocity conditions using our recently described coupled adenylation–hydrox-
amate formation assay employing saturating concentrations of both ATP and
biotin (Wilson and Aldrich, 2010). Varying concentrations of inhibitor Bio-AMS
(20 mM DMSO stock), providing a final DMSO concentration of 1% (v/v), orElsevier Ltd All rights reserved
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50 mM Tris [pH 8.0}, 5.0 mM MgCl2, 0.5 mM DTT, 2.5 mM ATP, 0.1 unit of
nucleoside phosphorylase, 0.04 unit of pyrophosphatase, 0.2 mM 7-methyl-
thioguanosine [MesG], and 150 mM hydroxylamine [pH 7.0]) for 10 min at
25C. The master mix (95 mL) was then added to 5.0 ml of a biotin solution to
provide a final biotin concentration of 250 mM. Reactions (100 mL) were run
in 96-well half-area UVStar plates (Greiner), and the formation of 7-methyl-6-
thioguanine was measured at 360 nm (ε360 = 11,000 mol
1 cm1) at 25C on
a Molecular Devices SpectraMax M5e. The initial velocity data were fit by
nonlinear regression analysis to the sigmoidal Hill equation (Equation 1), as
follows:
vi
v0
=B+
A B
1+ 10ðlogIC50IÞ3 h
; (1)
using GraphPad prism version 4.0 to obtain the IC50 value, where vi/v0 is
the initial fractional velocity, h is the Hill slope, I is the logarithm of the
inhibitor concentration, and A and B are the top and bottom of the curve,
respectively.
Isothermal Titration Calorimetry
ITC experiments were conducted on a Microcal VP-ITC microcalorimeter
(Northhampton, MA). All titration experiments were performed at 20C in ITC
buffer (10 mM Tris [pH 7.5], 200 mM KCl, and 2.5 mM MgCl2). MtBPL was
exchanged into ITC buffer using an Amicon Ultra concentrator (Millipore,
Billerica, MA, USA), and final enzyme concentrations were determined using
an ε280 of 35540 M
1 cm1. In individual titrations, ligands were injected into
solutions of the enzyme. The quantity c = KAMt(0), in which Mt(0) is the initial
enzyme concentration is crucial for successful ITC experiments (Wiseman
et al., 1989). Experiments for the determination of DH (the change in binding
enthalpy in kilocalories per mole) were performed with a c value in the range
of 1.2–2.4 3 104, while displacement ITC experiments were performed with
a c value in the range of 206–415. Ligand and protein concentrations for the
determination of DH were 16 mM MtBPL and 160 mM Bio-AMS. The KA (the
association constant in M1) and n (the number of binding sites per monomer)
values were determined by ITC displacement experiments with 150 mM biotin
added to both the enzyme and ligand solutions. Enzyme concentrations for
displacement experiments were increased to 42 mM for titration with 420 mM
Bio-AMS. All titrations were performed in duplicate using a stirring speed of
307 rpm and a 300 s interval between 10 ml injections. The first injection was
omitted from data fitting. Titrations were run past the enzyme saturation point
to correct for heats of dilution. The data for the stoichiometric titration of Bio-
AMS inMtBPL provided DH values. The experimental data for the competitive
displacement ITC experiments were fitted to a theoretical titration curve
using the Origin software package (version 7.0) to provide KA
app and n values
(Velazquez-Campoy and Freire, 2006). TheKA value for Bio-AMSwas obtained
from the KA
app value using Equation 2:
KA =K
app
A

1+KBA ½B

; (2)
where [B] ([biotin]) equals 150 mM and KA
B (association constant for biotin) =
1.08 3 106. The thermodynamic parameters (DG and –TDS) were calculated
using Equation 3:
DG= --RT ln K =DH--TDS; (3)
whereDG,DH, andDS are the changes in free energy, enthalpy, and entropy of
binding, respectively, R = 1.98 cal mol1 K1, and T is the absolute tempera-
ture. The affinity of Bio-AMS for MtBPL is provided as the dissociation
constant (KD = 1/KA). Direct and competitive ITC experiments were performed
in two independent experiments and analyzed independently. The thermo-
dynamic values were then averaged. ITC experiments for determining the
binding affinity of biotin (KA
B in Equation 2) for MtBPL were performed as
described above. Ligand and enzyme concentrations were 195 mM and
19.5 mM, respectively. The data were then fit using the single-site binding
model provided in Origin 7.0 to determine KA
B.
Antitubercular Assays
For determination of minimum inhibitory concentrations (MICs) against Mtb
strains, broth microdilution assays were determined in quadruplicate in
GAST media supplemented with Fe3+ (De Voss et al., 2000) using Bio-AMSChemistry & Biology 18, 1432–144from a DMSO stock solution or with control wells treated with an equivalent
volume of DMSO or with isoniazid as positive control. Cells were grown to
an OD650 of 0.2, diluted 1000-fold in the GAST/Fe medium and 50 ml added
per well of a 96-well plate containing 50 ml of GAST/Femediumwith compound
in a two-fold dilution series across the wells giving an initial cell density of
104 cells/well. Plates were incubated at 37C, and growth was monitored at
7 and 14 days. The MIC was recorded as the lowest concentration of
compound that resulted in complete inhibition of growth. MICs were deter-
mined against the laboratory strainMtbH37Rv as well as a panel of drug-resis-
tant clinical isolates of Mtb (Jeon et al., 2008).
Biotinylated Proteome Assay
A 30ml culture ofMtbH37Rvwas grown at 37C to anOD650 of 0.194, and was
split into 33 10 mL. The 10 ml cultures were treated with either 0.1 mMDMSO
or 1.0 mM Bio-AMS for 26 hr at 37C. After this time, the OD650 values for the
DMSO and 1.0 mM treated cells were 0.616 and 0.600, respectively. The cells
were harvested and the cell pellets were washed once with PBS (10 mM
sodium phosphate and 150 mM NaCl [pH 7.8]) and were frozen at 80C.
The cells were subjected to bead beating in PBS containing protease inhibitor
cocktail (Roche). After removing unlysed cells and cell wall debris by centri-
fuging, the total protein concentrations were determined for the 0.1 mM
DMSO and 1.0 mM Bio-AMS-treated cells and were found to be 2.0, 2.2, and
2.2 mg/mL, respectively. An equal volume of 23 SDS reducing gel electropho-
resis loading buffer was added to the samples, which were subsequently
heated for 10 min at 80C. A 5.0 ml aliquot of each sample was separated
by denaturing gel electrophoresis (4%–15% Tris-HCl Ready Gel, BioRad)
and was transferred to a PVDF membrane (iBlot System, Invitrogen). The
membrane was blocked with Tris-buffered saline containing 0.05% Tween-
20 (TBST) containing 1.0% BSA for 30 min at 25C. The membrane was incu-
bated with an AlexaFluor 647 fluorescent-streptavidin conjugate (Invitrogen) at
a dilution of 1:1000 in TBST for 1 hr at 25C, after which the membrane was
washed 33 10ml TBST. Biotinylated proteins within themembrane were visu-
alized by fluorescence scanning using an FMBIO III fluorescent scanner
(MaraiBio). Band intensities were calculated using the Image Analysis software
version 3.0 provided with the scanner. Band intensities were normalized for
protein concentration to provide the normalized percentage band intensity
values in Figure 2D.
Essentiality of birA
For mutant construction, Mycobacterium smegmatis mc2155 was grown at
37C on Difco 7H11 agar (BD) or in Difco Middlebrook 7H9 broth (BD) with
0.2% v/v glycerol and 0.05% v/v Tween 80. Antibiotics were added, where
appropriate, at 50 mg/ml (hygromycin B, Calbiochem), 20 mg/ml (streptomycin,
Sigma), 25 mg/ml (kanamycin A, Sigma), or 25 mg/ml (zeocin, Invitrogen). Prep-
aration of competent cells, electroporations, and the preparation of genomic
DNAs were performed as described elsewhere (Ehrt et al., 2005). Plasmids
were constructed using standard procedures (details are available upon
request). Polyclonal anti-MtBPL antibodies were generated using a commer-
cial immunization service (Covance).
Initially, we attempted to delete MsbirA from the chromosome of
M. smegmatis and cloned a knockout plasmid, pKO-MsbirA (derived from
pSM270; Manganelli et al., 2001) in which800 bp DNA fragments containing
the upstream and downstream region ofMsbirA were separated by a hygrom-
ycin resistance gene. Integration of pKO-MsbirA into the M. smegmatis chro-
mosome by a single crossover conferred resistance to hygromycin (hygR) and
streptomycin (strepR) as well as sensitivity to sucrose (sucS). A second
crossover that would have deleted MsbirA would have resulted in a strain
that is hygR, streptomycin sensitive, and sucrose resistant. We analyzed
150 sucrose-resistant descendants of two different single crossover strains,
but were unable to identify a single MsbirA deletion mutant among them.
This strongly suggested that MsbirA is essential for growth of M. smegmatis.
We next constructed a birA merodiploid (Figure S3, step 1) by transforming
M. smegmatis with a kanamycin resistance (kanR) conferring MsbirA expres-
sion plasmid that integrated into the attachment site of the mycobacterio-
phage L5 (attL5). Deletion of the WT copy of MsbirA in the merodiploid (Fig-
ure S3, step 2) with pKO-MsbirA proved to be straightforward and was
confirmed by southern blotting (Figure S4). We refer to the resulting strain as
DMsbirA MsbirA-attL5 to indicate that the only functional copy of MsbirA is1, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1439
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by site-specific recombination (Pashley and Parish, 2003), which allowed us to
determine whether M. smegmatis is able to grow after deletion of MsbirA.
Replacement of the kanRMsbirA expression plasmid with a zeocin resistance
(zeoR) conferring plasmid that containedMsbirA was efficient (Figure S3, step
4). In contrast, no zeoR colonies were obtained in several independent trans-
formations of DMsbirA MsbirA-attL5 with a zeoR plasmid that did not contain
MsbirA (Figure S3, step 3). This demonstrated that deletion ofMsbirA prevents
growth of M. smegmatis on agar plates.
To generate M. smegmatis mutants that expressed MtBPL instead of
MsBPL we transformed DbirA MsbirA-attL5 with zeoR plasmids containing
MtbirA. Mutants in which MsbirA-attL5 was replaced by MtbirA-attL5
were identified by confirming sensitivity to kanamycin (which is a result of
deleting the MsbirA plasmid from the attL5) and in immunoblots performed
with a polyclonal antibody that was generated against MtBPL and did not
recognize MsBPL. Plasmids that contained different promoters upstream of
MtbirA were used to generate strains that constitutively expressed different
levels of MtBPL (Figure 3A). Transformation of plasmids in which (1) the
native upstream region of MtbirA, (2) the promoter Psmyc (Kaps et al.,
2001), or (3) Ptb38 were used to transcribe MtbirA yielded Msm MtBPL-L,
Msm MtBPL-M, and Msm MtBPL-M, respectively. Promoter Ptb38 is con-
tained within a DNA fragment that has been identified in a promoter trap
screen (Ehrt et al., 2005). This promoter has strong activity in M. smegmatis
and slightly lower activity in Mtb (unpublished data). Plasmids containing
MtbirA transcribed by Ptb38 and Psmyc were transformed in Mtb H37Rv to
generate Msm MtBPL-M and Msm MtBPL-M, respectively. The Enolase was
used as loading control and was detected using a polyclonal antibody
provided by Dr. Sabine Ehrt. All M. smegmatis mutants in which MsbirA was
replaced by MtbirA grew similarly to WT M. smegmatis (Figure S5). Overex-
pression of MtBPL also did not affect growth of Mtb (data not shown). The
activity of Bio-AMS against the M. smegmatis strains was assessed as
described for Mtb with two exceptions: growth was analyzed after 2 to
4 days instead of 10 to 14 days and no iron supplement was added to the
GAST medium.
Crystallization
BirA was incubated with a slight molar excess of Bio-AMS for 30 min at 37C
prior to crystallization. Crystals were grown in 1–2 weeks at 20C by micro-
seeding with apo crystals in hanging drops using the vapor-diffusion method.
The protein solution contained 4.6mg/mLBirA, 10mMHEPES (pH 7.5), 50mM
NaCl, 1 mM DTT, 1.05% DMSO, and 200 mM Bio-AMS. Equal volumes were
mixed of protein solution and mother liquor containing 20% MPEG 2000,
50 mM trimethylamine N-oxide, and 100 mM Tris (pH 8.5). Crystals were
cryo-protected in a solution containing mother liquor supplemented with
20% PEG 400 and flash frozen in liquid nitrogen.
Data Collection and Structure Solution
X-ray diffraction data were collected at 100 K and 1.000 A˚ wavelength on
beamline 4.2.2 at the Advanced Light Source, Berkeley, CA. Data were inte-
grated and scaled by d*TREK (Pflugrath, 1999). The structure was solved by
molecular replacement using the previously determined apo MtBPL structure
(PDB code 2CGH) and the program Phaser (McCoy et al., 2007) from within
CCP4 (Collaborative Computational Project, 1994). Initial refinement and
manual model rebuilding was performed using REFMAC5 (Murshudov et al.,
1997) and Coot (Emsley and Cowtan, 2004), respectively. Topology and
parameter files for Bio-AMSwere generated using the PRODRG server (Schu¨t-
telkopf and van Aalten, 2004). Final refinement was performed using Phenix
(Adams et al., 2010). Ramachandran plots were calculated by MOLPROBITY
and showed 96.4% of the residues were in the favored regions and all residues
were in the allowed regions. OMIT density (Figure S6) was calculated using the
program SFCHECK (Vaguine et al., 1999). Images and figures were prepared
using PyMOL (DeLano Scientific, Palo Alto, CA, USA).ACCESSION NUMBER
The atomic coordinates and structure factors were deposited with the Protein
Data Bank with the accession code 3RUX.1440 Chemistry & Biology 18, 1432–1441, November 23, 2011 ª2011SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and may be found with this article online at
doi:10.1016/j.chembiol.2011.08.013.
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